Search results for "Hepatocellular Carcinoma."

showing 10 items of 690 documents

Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis

1996

Cathepsin D serum mass concentrations were determined by enzyme immunoassay in patients with hepatocellular carcinoma (n = 51) and/or liver cirrhosis (n = 92) or benign steatosis (n = 16) and correlated with some biochemical and clinical properties of these diseases. Increased cathepsin D serum mass concentrations (P < 0.001) were observed in all these groups of patients as compared to normal subjects (n = 98). However, patients with steatosis had serum mass concentrations of this enzyme significantly lower (mean 2—3 fold) than those measured in cancer patients (P < 0.05) or cirrhotic patients (P < 0.001). Interestingly, significantly higher cathepsin D serum mass concentrations (m…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularClinical BiochemistryeducationLiver cirrhosis tumor markrersCathepsin DBiologymedicine.disease_causeCathepsin DImmunoenzyme TechniquesInternal medicinemedicineHumansAgedchemistry.chemical_classificationmedicine.diagnostic_testHepatitis AlcoholicBiochemistry (medical)Liver NeoplasmsGeneral Medicinehepatocellular carcinomaMiddle Agedmedicine.diseaseEnzymeEndocrinologychemistryImmunoassayHepatocellular carcinomaFemalealpha-FetoproteinsSteatosisCarcinogenesisLiver function tests
researchProduct

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

2017

Background & Aims: The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who attained sustained viral response (SVR). We aimed to assess the risk of cirrhosis-related complications in this specific group of patients. Methods: Data from previously reported Western cohort studies including patients with chronic HCV infection and bridging fibrosis or cirrhosis who attained SVR were pooled for survival analyses on the individual patient level. The primary endpoint was HCC and the secondary endpoint was clinical disease progression, defined as liver failure, HCC or death. Results: Included were 1…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularSustained Virologic ResponseHepatitis C virusmedicine.disease_causeGastroenterologyCohort Studies03 medical and health sciencesLiver disease0302 clinical medicineSDG 3 - Good Health and Well-beingRisk FactorsDiabetes mellitusInternal medicinemedicineClinical endpointHumansAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyFemalebusinessLiver cancer
researchProduct

Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection accord…

2013

This is the first matched pair analysis on the puzzling clinical problem of whether to perform liver transplantation (LT) or liver resection (LR) for Child's A hepatocellular carcinoma (HCC) patients. A total of 201 patients diagnosed with HCC and Child's A liver cirrhosis were treated with LT transarterial chemoembolization (TACE) or LR between 1998 and 2012. To achieve the most accurate study design, two groups of 57 patients were matched retrospectively according to their tumor characteristics detected by the initial computerized tomography (CT) scan. Sixteen of 57 LT candidates were not transplanted due to tumor progress during pre-treatment (TACE). Nevertheless, the retrospective analy…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentMatched-Pair AnalysisMilan criteriaLiver transplantationGastroenterologyResectionRecurrenceInternal medicinemedicineRetrospective analysisHepatectomyHumansIn patientAgedRetrospective StudiesAged 80 and overTransplantationIntention-to-treat analysisbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisIntention to Treat AnalysisLiver TransplantationSurvival RateHepatocellular carcinomaFemalebusinessFollow-Up StudiesClinical transplantation
researchProduct

Diagnosis of Liver Cirrhosis

2005

Background/goals Liver cirrhosis, the final stage of chronic liver disease, is characterized by an unfavorable prognosis and an increased risk of hepatocellular carcinoma and also requires an appropriate management. Laparoscopy, the gold standard in the diagnosis of cirrhosis, is hampered by its invasiveness. Therefore, a noninvasive method for diagnosing liver cirrhosis would be of great benefit. Study A consecutive series of 100 patients, sent to our gastroenterological unit for diagnostic laparoscopy, underwent a standardized ultrasonographic examination prior to laparoscopy. Results Conventional ultrasonographic examination revealed a sensitivity of 55% and a specificity of 86% in the d…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisChronic liver diseaseSensitivity and SpecificityGastroenterologyInternal medicineHumansMedicineStage (cooking)LaparoscopyAgedUltrasonographyAged 80 and overChi-Square Distributionmedicine.diagnostic_testbusiness.industryUltrasoundGastroenterologyGold standard (test)Middle Agedmedicine.diseaseEndoscopyHepatocellular carcinomaFemaleLaparoscopyRadiologybusinessJournal of Clinical Gastroenterology
researchProduct

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alco…

2008

Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption. Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake. The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone. Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60]. Protocol biopsies were done in HCV …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationmedicine.disease_causeGastroenterologyBody Mass IndexLiver diseasePostoperative ComplicationsLiver Cirrhosis AlcoholicInternal medicineHumansMedicineAgedTransplantationHepatologybusiness.industryIncidence (epidemiology)Graft Survivalvirus diseasesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinomaEtiologyFemaleSurgerybusinessBody mass indexImmunosuppressive AgentsLiver Transplantation
researchProduct

Characteristics of hepatocellular carcinoma in Italy.

1998

This study aimed to assess the main features of hepatocellular carcinoma at the time of diagnosis in Italy, particularly in relation to the presence or absence of underlying cirrhosis, hepatitis virus marker patterns, age of the subjects and alpha-foetoprotein values.A total of 1148 patients with hepatocellular carcinoma seen at 14 Italian hospitals in the 1-year period from May 1996 to May 1997 were the subjects of this prevalence study. Both newly diagnosed cases (incident cases) and cases diagnosed before May 1996 but still attending the hospitals during the study period (prevalent cases) were included.We found that 71.1% of cases were positive for hepatitis C virus antibodies but negati…

AdultLiver CirrhosisMalemedicine.medical_specialtyHBsAgCarcinoma HepatocellularHepatitis C virusmedicine.disease_causeGastroenterologyAge DistributionInternal medicineHepatitis VirusesmedicinePrevalenceHumansSex DistributionAgedHepatitisAged 80 and overHepatitis B Surface AntigensHepatologybusiness.industryIncidence (epidemiology)Liver NeoplasmsLiver cancer; risk factors; ItalyHepatitis BHepatitis C AntibodiesMiddle Agedmedicine.diseaseLogistic ModelsItalyHepatocellular carcinomaImmunologyRegression AnalysisFemalealpha-FetoproteinsLiver cancerbusinessViral hepatitisJournal of hepatology
researchProduct

The added diagnostic value of 64-row multidetector CT combined with contrast-enhanced US in the evaluation of hepatocellular nodule vascularity: impl…

2009

The aim of this study was to assess the added diagnostic value of contrast-enhanced US (CEUS) combined with 64-row multidetector CT (CT) in the assessment of hepatocellular nodule vascularity in patients with liver cirrhosis. One hundred and six cirrhotic patients (68 male, 38 female; mean age +/- SD, 70 +/- 7 years) with 121 biopsy-proven hepatocellular nodules (72 hepatocellular carcinomas, 10 dysplastic and 15 regenerative nodules, 12 hemangiomas, and 12 other benignancies) detected during US surveillance were prospectively recruited. Each nodule was scanned by CEUS during the arterial (10-40 s), portal venous (45-90 s), and delayed sinusoidal phase (from 100 s after microbubble injectio…

AdultLiver CirrhosisMalemedicine.medical_specialtyMicrobubble contrast agentCirrhosisCarcinoma HepatocellularBiopsyContrast MediaLiver; Ultrasound; Microbubble contrast agent; CTMalignancyVascularityBiopsyUltrasoundhepatocellular nodule vascularitymedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesNeuroradiologyAgedUltrasonographyAged 80 and overMicrobubblesmedicine.diagnostic_testbusiness.industryLiver NeoplasmsInterventional radiologyNodule (medicine)General MedicineMiddle Agedmedicine.diseaseLiverHepatocellular carcinomaFemaleRadiologymedicine.symptombusinessCTEuropean radiology
researchProduct

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

2006

AIM: To evaluate the immunohistochemical localization of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) on tumor tissue specimens from patients with hepatocellular carcinoma (HCC) and the serum levels of IL-6 and sIL-6R in a group of patients with HCC as well as liver cirrhosis (LC) in a group of patients with LC alone and in a control group. METHODS: Three groups of subjects were studied: group I (n = 83) suffering from HCC and LC, group II (n = 72) suffering from LC alone and group III (n = 42) as healthy controls. All patients had hepatitis C virus infection. Serum IL-6 and IL-6R levels were determined using a commercially available ELISA kit. Immunohistochemistry was performed using the…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentChronic liver diseaseGastroenterologyInternal medicineCarcinomaMedicineHumansInterleukin 6ReceptorCytokineAgedNeoplasm Stagingbiologybusiness.industryInterleukin-6Chronic liver diseaseLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryReceptors Interleukin-6digestive system diseasesCytokineHepatocellular carcinomabiology.proteinImmunohistochemistryFemalebusinessRapid CommunicationWorld journal of gastroenterology
researchProduct

Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe

2001

The aim of this study was to evaluate the distribution and clinical significance of hepatitis C virus (HCV) genotypes in European patients with compensated cirrhosis due to hepatitis C (Child class A) seen at tertiary referral centres. HCV genotypes were determined by genotype-specific primer PCR in 255 stored serum samples obtained from cirrhotics followed for a median period of 7 years. Inclusion criteria were biopsy-proven cirrhosis, absence of complications of cirrhosis and exclusion of all other potential causes of chronic liver disease. The proportion of patients with types 1b, 2, 3a, 1a, 4 and 5 were 69%, 19%, 6%, 5%, 0.5% and 0.5%, respectively. Kaplan-Meier 5-year risk of hepatocel…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisHepacivirusHepatitis C virusHepacivirusAntibodies ViralChronic liver diseasemedicine.disease_causeAntiviral AgentsGastroenterologyDisease-Free SurvivalStatistics NonparametricSex FactorsSDG 3 - Good Health and Well-beingVirologyInternal medicineHumansMedicineDecompensationLongitudinal StudiesAgedProportional Hazards ModelsHepatologybiologybusiness.industryAge FactorsInterferon-alphaTransfusion ReactionHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CEuropeTreatment OutcomeInfectious DiseasesRelative riskHepatocellular carcinomaRNA ViralFemalebusiness
researchProduct

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

2016

Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of su…

AdultMale0301 basic medicinemedicine.medical_specialtyTime FactorsCarcinoma HepatocellularTime FactorMicroarrayHepatocellular carcinomamolecular carcinogenesisGastroenterologyliver imagingHEPATOCELLULAR CARCINOMA; LIVER IMAGING; MOLECULAR CARCINOGENESIS; MOLECULAR ONCOLOGY; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization Pathologic; Prospective Studies; Survival Rate; Time Factors; Tumor Burden; Medicine (all); Gastroenterology03 medical and health sciencesmolecular oncology0302 clinical medicineHepatocellular carcinoma liver imaging molecular carcinogenesis molecular oncologyInternal medicinemedicineCarcinomaHumansDoubling timeProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overNeovascularization Pathologicbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseTumor BurdenSurvival RateProspective Studie030104 developmental biologyQuartileLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionFemalebusinessHumanGut
researchProduct